News | May 25, 2023
Piramal Pharma posts Q4 FY23 consolidated PAT at Rs. 50.11 Cr
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
5C Network’s groundbreaking platform aims to bring together diagnostic facilities and healthcare aggregators on a single platform to deliver an unparalleled patient experience
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
This is the second US FDA GMP inspection of this facility within one year
The company has reported total income of Rs. 58.42 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
